DNA methylation and expression of MAPRE3 affect overall survival of early-stage non-small cell lung cancer patients
Por:
Chen, C, Cheng, JC, Hou, RL, Zheng, XY, Su, L, Bjaanæs, MM, Karlsson, A, Planck, M, Staaf, J, Helland, Å, Esteller, M, Christiani, DC, Chen, F, Cao, XF and Zhang, RY
Publicada:
25 abr 2026
Ahead of Print:
1 abr 2026
Resumen:
The MAPRE3 gene is aberrantly expressed in several cancers. We profiled DNA methylation in tumor tissues from early-stage non-small cell lung cancer (NSCLC) patients and assessed associations with overall survival (OS). Significant CpG probes were validated in The Cancer Genome Atlas (TCGA). The methylation level of cg12821679MAPRE3 showed significant associations with OS in lung squamous cell carcinoma (LUSC) (HR = 0.32, P = 6.55 & times; 10-7), but it was not observed in lung adenocarcinoma (LUAD). In LUSC, MAPRE3 expression was significantly correlated with cg12821679MAPRE3 (r = 0.17, P = 2.96 & times; 10-3) and potential trans-regulated genes were enriched in the Nicotine addiction pathway. Additionally, MAPRE3 expression showed significant associations with OS in both LUAD and LUSC (LUAD: HRlow vs high = 2.28, P = 2.40 & times; 10-3; LUSC: HRlow vs high = 1.61, P = 0.0244). The association between smoking cessation and overall survival was significantly modified by MAPRE3 expression (HRinteraction = 0.69, P = 0.0282). Smoking cessation improved OS only in patients with high MAPRE3 expression (HR = 0.56, P = 2.82 & times; 10-3). We conclude MAPRE3 may predict NSCLC prognosis and influence the prognostic benefit of smoking cessation.
Filiaciones:
Chen, C:
Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Biostat, 01 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China
Cheng, JC:
Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Biostat, 01 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China
Hou, RL:
Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Biostat, 01 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China
Zheng, XY:
Nanjing Med Univ, Peoples Hosp Changzhou 2, Affiliated Hosp 3, Informat Ctr, Nanjing, Jiangsu, Peoples R China
Su, L:
Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA
Bjaanæs, MM:
Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway
Karlsson, A:
Lund Univ, Dept Clin Sci Lund, Div Oncol, Lund, Sweden
Lund Univ, CREATE Hlth Strateg Ctr Translat Canc Res, Lund, Sweden
Planck, M:
Lund Univ, Dept Clin Sci Lund, Div Oncol, Lund, Sweden
Lund Univ, CREATE Hlth Strateg Ctr Translat Canc Res, Lund, Sweden
Staaf, J:
Lund Univ, Dept Clin Sci Lund, Div Oncol, Lund, Sweden
Lund Univ, CREATE Hlth Strateg Ctr Translat Canc Res, Lund, Sweden
Helland, Å:
Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway
Univ Oslo, Inst Clin Med, Oslo, Norway
:
Josep Carreras Leukaemia Res Inst IJC, Canc Epigenet Grp, Barcelona, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain
Univ Barcelona, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Spain
Christiani, DC:
Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA
Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Div, Boston, MA USA
Harvard Med Sch, Boston, MA USA
Chen, F:
Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Biostat, 01 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China
Nanjing Med Univ, China Int Cooperat Ctr Environm & Human Hlth, Nanjing, Jiangsu, Peoples R China
Cao, XF:
Nanjing Med Univ, Affiliated Hosp 1, Sch Clin Med 1, Dept Anesthesiol & Perioperat Med, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China
Zhang, RY:
Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Biostat, 01 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China
Nanjing Med Univ, Peoples Hosp Changzhou 2, Affiliated Hosp 3, Informat Ctr, Nanjing, Jiangsu, Peoples R China
Nanjing Med Univ, Changzhou Med Ctr, Changzhou, Jiangsu, Peoples R China
Nanjing Med Univ, Lab Digital Intelligence & Hlth Governance, Nanjing, Jiangsu, Peoples R China
gold
|